KMT2D and breast carcinoma: The most commonly altered genes in this cohort, including all genes with a mutational frequency of ≥5% were TERT-promoter (69.7%), CDKN2A (45.9%), TP53 (37.8%), NF1 (35.6%), CDKN2B (33.3%), MED12 (28.9%), MTAP (27.7%), KMT2D (22.2%), PIK3CA (20.0%), PTEN (18.5%), RB1 (18.5%), EGFR (17.0%), SETD2 (8.9%), NRAS (8.1%), BRAF (7.4%), BCOR (5.2%); notably distinct in frequency from the breast carcinoma cohort (Figures 1 and 2, Table 2).